Walgreens Boots Alliance, Inc.

Deerfield, Ill. - Walgreen Co. intends to apply to list the shares of Walgreens Boots Alliance Inc. common stock on The Nasdaq Stock Market under the ticker symbol “WBA” following the closing of its merger with UK-based pharmacy retailer Alliance Boots. The company will voluntarily withdraw its common stock from listing on both the New York Stock Exchange (NYSE) and the Chicago Stock Exchange (CHX).  

DEERFIELD, Ill. - Walgreens president and CEO Greg Wasson informed the company’s board of directors that he will retire shortly after the completion of the merger between Walgreens and Alliance Boots, of which shareholders are scheduled to vote on Dec. 29, 2014.    

Walgreens has appointed Barry Rosenstein, managing partner JANA Partners, and a second new director to be named to its board of directors as the company continues moving forward to complete its merger with Alliance Boots.
 

Deerfield, Ill. -- Following Walgreens' announcement last week about taking the next step in acquiring Alliance Boots, Alex Gourlay, executive VP Walgreens Boots Alliance and president of Walgreens, announced a proposed operational organization structure in a letter to Walgreens employees.
 

Following Walgreens' announcement last week about taking the next step in acquiring Alliance Boots, Alex Gourlay, EVP Walgreens Boots Alliance and president of Walgreens, announced changes in the company's operational organization structure in a letter to Walgreens employees.
 

Walgreens has exercised its option to complete the second step of its strategic transaction with Alliance Boots ahead of the original option period, which was between February and August 2015. The transaction, subject to shareholder and various regulatory approvals, would fully combine the two companies to form the first global pharmacy-led, health and well-being enterprise.
 

Deerfield, Ill. — Walgreens on Wednesday said it has exercised its option to buy the remaining 55% of European pharmacy retailer and wholesaler Alliance Boots in a $15.26 billion deal that will keep the drug store chain's corporate tax headquarters in the United States. Walgreens said it is not in the best long-term interest of its shareholders to re-domicile outside the United States.